Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + Pola-R-CHP + High-dose Methotrexate in Secondary CNS Lymphoma
NCT06730542Phase 1Recruiting
- Start
- Apr 2025
- Primary completion
- Apr 2030
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zanubrutinib in secondary central nervous system lymphoma (SCNSL). Primary endpoint: Dose-Limiting Toxicities at 21 days. Started Apr 2025; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
secondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on NCT06730542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06730542.